The complement system is an important part of the immune system with a number of biological effects that mainly contribute to an inflammatory response and thus to the activation of cells such as leukocytes and endothelial cells. An intact complement system is essential for protection against infection. Nevertheless, this system is a double-edged sword: increased, uncontrolled or incorrect activation can potentially be dangerous to the patient.
Complement activity plays an important role in the pathogenesis of systemic autoimmune diseases.
Activation takes place via 3 ways:
The essential functions can be summarized in 4 mechanisms:
However, the complement system is also activated by circulating immune complexes (CIC) in the bloodstream. These circulating immune complexes (CIC) are aggregates (aggregations) of antibodies and structures dissolved in the blood against which these antibodies are directed (antigen - antibody complexes).
Normally, immune complexes are taken up by phagocytes or macrophages immediately after their formation. However, if too many immune complexes are produced, this exceeds the capacity of the phagocytes and the immune complexes can enter the blood in larger quantities.
In complement activation, fission products such as C3d can be detected in patients with lupus nephritis or in patients with cutaneous systemic scleroderma.
There are different types of immune complexes depending on which antibodies and antigens are included:
Determination of CIC and complement system
Tumors of neuroendocrine origin, such as carcinoids, typically have elevated levels of chromium organine A in serum and plasma.
There are other causes for elevated Chromogranin A, but in the presence of neuroendocirne tumors, monitoring Chromogranin A levels can be helpful in assessing the efficacy of treatment.
Chromogranin A has been detected in a variety of neoplastic tissues (especially neuroendorkin origin):
An increase in chromogranin A is also found in some non-malignant diseases:
Determination of Chromogranin A